Clinical trials: Pancreatitis
Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)
The primary efficacy objective of this study is to evaluate the difference in coefficient of fat absorption (CFA) of participants treated with high dose EUR-1008 (APT-1008) versus low dose of EUR-1008 (APT-1008) in the treatment…
- Trial name
- NCT00788593
- Testing
- EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose
- Where
- 18 sites in United States, Italy and 1 more
- Volunteers
- 82 people
- Sponsor
- Forest Laboratories
Renal Pelvis Cancer, Restless Legs Syndrome
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in the Adverse Events…
- Conditions
- Renal Pelvis Cancer, Restless Legs Syndrome, Epilepsy, Neuropathic Pain
- Trial name
- NCT01138124
- Testing
- Gabapentin prescriptions
- Volunteers
- 54,202 people
- Sponsor
- GlaxoSmithKline
Acute Pancreatitis
A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis
This open-label study will evaluate the pharmacodynamic and pharmacokinetic profile of CM4620-IE in patients with acute pancreatitis.
- Trial name
- NCT03709342
- Testing
- CM4620-IE
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- CalciMedica, Inc.
Severe Hypertriglyceridemia
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
This is a randomized, open-label crossover study. The primary objective of this study is to compare the relative bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and the…
- Trial name
- ECLIPSEIV (NCT02189252)
- Testing
- Epanova, Lovaza
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons…
- Trial name
- NCT01077323
- Testing
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Where
- United States
- Volunteers
- 363,766 people
- Sponsor
- AstraZeneca
Walled Off Pancreatic Necrosis
AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study
To demonstrate safety and effectiveness of lumen-apposing metal stents for resolution of walled off pancreatic necrosis (WONs) in patients with WONs with solid component >30%.
- Trial name
- NCT03525808
- Testing
- AXIOS
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Boston Scientific Corporation
Chronic Pancreatitis
Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis
Tanezumab is effective in reducing the pain associated with chronic pancreatitis.
- Trial name
- NCT01146561
- Testing
- Tanezumab
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
This open-label, dose-response study will evaluate the safety and efficacy of CM4620-IE in patients with acute pancreatitis and accompanying SIRS. The study will consist of two phases.
- Trial name
- NCT03401190
- Testing
- CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- CalciMedica, Inc.
Acute Pancreatic Necrosis, Acute Pancreatitis
EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial
A prospective, single arm, open label, multi-center, trial to evaluate the safety and effectiveness of the Interscope EndoRotor® Resection System in subjects requiring direct endoscopic necrosectomy (DEN) with walled off…
- Conditions
- Acute Pancreatic Necrosis, Acute Pancreatitis, Necrotizing Pancreatitis
- Trial name
- NCT03694210
- Testing
- EndoRotor Therapy
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Interscope, Inc.
Exocrine Pancreatic Insufficiency, Pancreatic Diseases
Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients receiving the treatment with LipaCreon for a long term in order to evaluate the effective and…
- Conditions
- Exocrine Pancreatic Insufficiency, Pancreatic Diseases, Digestive System Diseases
- Trial name
- NCT01427725
- Testing
- Lipacreon
- Where
- 189 sites in Japan
- Volunteers
- 579 people
- Sponsor
- Mylan Inc.
Pancreatectomy for Chronic Pancreatitis
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves 100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT).
- Trial name
- NCT01967888
- Testing
- Reparixin
- Where
- 9 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Dompé Farmaceutici S.p.A
Chronic Pancreatitis
Secretin Infusion for Pain Due to Chronic Pancreatitis
To determine if intravenous secretin administration in escalating doses three times daily for three days will improve the pain from CP at the time of infusion, after each infusion (1 to 3 hours), at Day 7 after infusion, and at…
- Trial name
- NCT01265875
- Testing
- Human Secretin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- ChiRhoClin, Inc.
Chronic Pancreatitis
WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures
To prospectively document the performance of a FCSEMS for treatment of pancreatic duct strictures in patients with painful chronic pancreatitis.
- Trial name
- NCT02802020
- Testing
- Pancreatic fully-covered self-expanding metal stent (FCSEMS)
- Where
- 11 sites in United States, Belgium and 4 more
- Volunteers
- 67 people
- Sponsor
- Boston Scientific Corporation
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
Approximately 216 patients with acute pancreatitis and accompanying SIRS will be randomized at approximately 30 sites. Patients will be randomly assigned to either Auxora at one of three dose levels or one of three placebo…
- Trial name
- CARPO (NCT04681066)
- Testing
- CM-4620 Injectable Emulsion or CM-4620-IE
- Where
- 37 sites in United States, India
- Volunteers
- 216 people
- Sponsor
- CalciMedica, Inc.
Cystic Fibrosis, Chronic Pancreatitis
Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
Exocrine pancreatic insufficiency (EPI) is a condition that is caused by the inadequate pancreatic enzymes needed for normal digestion and is commonly associated with a wide range of chronic diseases, including cystic fibrosis…
- Trial name
- NCT05069597
- Testing
- CREON
- Where
- 21 sites in United States
- Volunteers
- 30 people
- Sponsor
- AbbVie
Diabetes Mellitus, Type 2
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
To compare the risk of acute pancreatitis in patients with Type 2 diabetes mellitus (T2DM) newly initiating empagliflozin to that of patients newly initiating other oral non-incretin/non-Sodium glucose co-transporter-2 inhibitor…
- Trial name
- NCT05162014
- Testing
- empagliflozin, Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
- Where
- Germany
- Volunteers
- 494,679 people
- Sponsor
- Boehringer Ingelheim
Hypertriglyceridemia
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL)…
- Trial name
- NCT04863014
- Testing
- evinacumab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 21 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Pancreatitis, Pancreatectomy
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
This study assessed the effect of pancrelipase delayed release capsules on fat and nitrogen absorption in subjects with PEI due to Chronic Pancreatitis and Pancreatectomy.
- Conditions
- Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency
- Trial name
- NCT00414908
- Testing
- Pancrelipase delayed release capsule
- Where
- 30 sites in United States, Bulgaria and 6 more
- Volunteers
- 52 people
- Sponsor
- Solvay Pharmaceuticals
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Pancreatitis, Acute Necrotizing
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults
GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level throughout the treatment period.
- Trial name
- NCT03245619
- Testing
- GSK3335065
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline